CRIS Current Research Information System

ARGNANI, LISA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.397
EU - Europa 6.296
AS - Asia 5.880
SA - Sud America 378
AF - Africa 374
OC - Oceania 10
Continente sconosciuto - Info sul continente non disponibili 2
Totale 20.337
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.315
SG - Singapore 1.989
CN - Cina 1.701
IT - Italia 1.085
DE - Germania 1.074
GB - Regno Unito 1.025
VN - Vietnam 1.014
SE - Svezia 931
NL - Olanda 848
HK - Hong Kong 496
RU - Federazione Russa 322
IN - India 298
BR - Brasile 282
FR - Francia 218
IE - Irlanda 199
UA - Ucraina 171
KR - Corea 128
TG - Togo 98
FI - Finlandia 96
CI - Costa d'Avorio 93
ZA - Sudafrica 91
EE - Estonia 74
JP - Giappone 58
JO - Giordania 54
CA - Canada 50
AR - Argentina 47
PL - Polonia 45
SC - Seychelles 42
AT - Austria 41
ID - Indonesia 39
NG - Nigeria 36
BE - Belgio 31
ES - Italia 24
MX - Messico 24
CH - Svizzera 23
IR - Iran 19
BG - Bulgaria 17
BD - Bangladesh 13
TR - Turchia 13
HR - Croazia 11
LT - Lituania 11
PE - Perù 10
CL - Cile 9
EC - Ecuador 9
GR - Grecia 9
LB - Libano 9
PY - Paraguay 9
RO - Romania 9
AU - Australia 7
CZ - Repubblica Ceca 7
IL - Israele 6
MY - Malesia 6
RS - Serbia 6
EG - Egitto 5
IQ - Iraq 5
UY - Uruguay 5
CO - Colombia 4
PT - Portogallo 4
UZ - Uzbekistan 4
AE - Emirati Arabi Uniti 3
DO - Repubblica Dominicana 3
LA - Repubblica Popolare Democratica del Laos 3
NZ - Nuova Zelanda 3
PH - Filippine 3
VE - Venezuela 3
AL - Albania 2
CR - Costa Rica 2
DK - Danimarca 2
HU - Ungheria 2
KZ - Kazakistan 2
LU - Lussemburgo 2
MK - Macedonia 2
OM - Oman 2
PK - Pakistan 2
QA - Qatar 2
SA - Arabia Saudita 2
SK - Slovacchia (Repubblica Slovacca) 2
ZM - Zambia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AM - Armenia 1
AZ - Azerbaigian 1
BN - Brunei Darussalam 1
BW - Botswana 1
BY - Bielorussia 1
CG - Congo 1
DZ - Algeria 1
EU - Europa 1
GH - Ghana 1
KE - Kenya 1
KG - Kirghizistan 1
KH - Cambogia 1
KW - Kuwait 1
LC - Santa Lucia 1
LI - Liechtenstein 1
MN - Mongolia 1
NI - Nicaragua 1
NO - Norvegia 1
PS - Palestinian Territory 1
SN - Senegal 1
TJ - Tagikistan 1
Totale 20.335
Salva come PNG Salva come JPEG
Città #
Singapore 1.308
Southend 881
Ashburn 836
Fairfield 744
Kerkrade 666
Chandler 622
Hong Kong 490
Houston 447
Santa Clara 440
Frankfurt am Main 380
Woodbridge 356
Seattle 322
Wilmington 306
Hefei 282
Princeton 280
Beijing 260
Dong Ket 253
Ann Arbor 248
Cambridge 242
Boardman 202
Dublin 199
Bologna 198
Ho Chi Minh City 138
Seoul 128
Berlin 113
Los Angeles 113
New York 108
Hanoi 104
Milan 104
Lomé 98
Nanjing 94
Abidjan 93
Westminster 93
Dallas 77
Padova 77
Helsinki 75
Jinan 75
Jacksonville 69
Bremen 60
Buffalo 58
Rome 57
Tokyo 55
Amman 54
San Diego 51
Shenyang 50
Redondo Beach 47
Saint Petersburg 39
Turin 39
Falkenstein 38
Guangzhou 38
Secaucus 38
Warsaw 36
Abeokuta 34
Changsha 33
Dearborn 33
Kyiv 33
Tianjin 33
Hebei 32
Redmond 32
Shanghai 31
São Paulo 31
Brussels 29
Zhengzhou 29
Bengaluru 28
Hyderabad 28
Jakarta 28
London 28
Nanchang 28
Chicago 27
Des Moines 27
Hangzhou 27
Jiaxing 27
Nuremberg 27
Toronto 26
Florence 25
Munich 24
Phoenix 23
Yubileyny 23
Redwood City 22
Taizhou 21
Medford 20
Olalla 20
Düsseldorf 19
Lappeenranta 18
Haiphong 17
Orem 17
Verona 17
Vienna 17
Bern 16
Norwalk 16
Falls Church 15
San Francisco 15
Brooklyn 14
Fuzhou 14
Mülheim 14
Sofia 14
Catania 13
Da Nang 13
Haikou 13
Modena 13
Totale 13.285
Salva come PNG Salva come JPEG
Nome #
90-yttrium-ibritumomab tiuxetan consolidation of fludarabine, mitoxantrone, rituximab in intermediate/high-risk follicular lymphoma: updated long-term results after a median follow-up of 7 years 1.449
BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma: a real-life experience 380
A phase II trial of short course fludarabine, mitoxantrone, rituximab followed by 90Y-ibritumomab tiuxetan in untreated intermediate/high-risk follicular lymphoma. 227
The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, European, multicentre cohort study 226
Allotransplant in relapsed or refractory aggressive T-cell lymphomas: retrospective monocentric analysis of 14 patients 216
Is it really possible to cure hairy cell leukemia patients only with frontline therapy? 207
Design of New Personalized Therapeutic Approaches for Diffuse Large B-Cell Lymphoma through Gut Microbiome Profiling 206
The Berlin-Frankfurt-Münster protocol for the upfront treatment of aggressive lymphomas: The Bologna experience 202
High efficacy of the MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis, a 20 year experience 196
Midtreatment 18F-fluorodeoxyglucose positron-emission tomography in aggressive non-Hodgkin lymphoma. 195
(90) Y-ibritumomab tiuxetan in patients with extra-nodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) - The Zeno Study 190
Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: a multicenter retrospective study 187
Siltuximab in relapsed/refractory multicentric Castleman disease: Experience of the Italian NPP program 187
A patient with plasmablastic lymphoma achieving long-term complete remission after thalidomide-dexamethasone induction and double autologous stem cell transplantation: a case report 185
Yttrium-90 ibritumomab tiuxetan as a single agent in patients with pretreated B-cell lymphoma: evaluation of the long-term outcome. 184
Brentuximab vedotin in relapsed/refractory Hodgkin's lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials. 184
Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial. 182
Long-term responders after Brentuximab vedotin: Single-center experience on relapsed and refractory hodgkin lymphoma and anaplastic large cell lymphoma patients 179
Interim positron emission tomography response-adapted therapy in advanced-stage hodgkin lymphoma: Final results of the phase II part of the HD0801 study 176
Stile di vita e obesità nell’adolescente 172
Bendamustine-rituximab regimen in untreated indolent marginal zone lymphoma: experience on 65 patients 172
Collection of Hematopoietic Stem Cells after Previous Radioimmunotherapy is Feasible and Does Not Impair Engraftment after Autologous Stem Cell Transplantation in Follicular Lymphoma. 171
Phase II trial of short-course R-CHOP followed by 90Y-ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients. 170
Brentuximab vedotin followed by ABVD +/- radiotherapy in patients with previously untreated Hodgkin lymphoma: final results of a pilot phase II study 168
The treatment of primary mediastinal large B-cell lymphoma: A two decades monocentric experience with 98 patients 166
Brentuximab Vedotin in Transplant-Naïve Relapsed/Refractory Hodgkin Lymphoma: Experience in 30 Patients 163
PD-1 blockade as bridge to allogenic stem cell transplantation in relapsed/refractory Hodgkin lymphoma patients: a retrospective single center case series 163
Chinese Women in Italy. Menarche, Pregnancy and Maternity. 158
Hairy Cell Leukemia: Allogeneic Transplantation Could be an Optimal Option in Selected Patients. 157
Efficacy and safety of biosimilar epoetin alpha in patients with chronic lymphoid neoplasms and chemotherapy-induced anaemia: An observational, retrospective, monocentric analysis 155
Relationships between anthropometric parameters and motor tests in young rugby players 153
Electrochemotherapy in Vulvar Cancer and Cisplatin Combined with Electroporation. Systematic Review and In Vitro Studies 153
BRAF V600E-positive monomorphic epitheliotropic intestinal T-cell lymphoma complicating the course of hairy cell leukemia 152
Brentuximab vedotin in the treatment of elderly Hodgkin lymphoma patients at first relapse or with primary refractory disease: a phase 2 study of FIL ONLUS 152
A case report of the long treatment experience of a Sézary syndrome responder patient: 16 years through all the systemic and innovative therapies 152
Economic evaluation of anti-CD19 CAR T-cell pathway for large B-cell lymphomas in the real-life setting: the experience of an Italian hub center in the first three years of activity 151
Non-hodgkin lymphomas presenting as soft tissue masses: a single center experience and meta-analysis of the published series. 150
Fludarabine-Mitoxantrone-Rituximab regimen in untreated indolent non-follicular non-Hodgkin's lymphoma: experience on 143 patients 150
Leukocytoclastic vasculitis associated with hairy cell leukemia at diagnosis: A case report and review of the literature 150
Lenalidomide in Pretreated Patients with Diffuse Large B-Cell Lymphoma: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice 148
The role of rituximab and positron emission tomography in the treatment of primary mediastinal large B-cell lymphoma: experience on 74 patients 146
Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed/refractory Hodgkin's lymphoma 146
Lenalidomide monotherapy for relapsed/refractory peripheral T-cell lymphoma not otherwise specified. 146
Italian real-life experience with brentuximab vedotin: results of a large observational study of 40 cases of relapsed/refractory systemic anaplastic large cell lymphoma 145
Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome. 145
Effectiveness of chemotherapy after anti-PD-1 blockade failure for relapsed and refractory Hodgkin lymphoma 145
Prognostic value of interim positron emission tomography in patients with peripheral T-cell lymphoma. 144
Italian real life experience with ibrutinib: results of a large observational study on 77 relapsed/refractory mantle cell lymphoma 144
Brentuximab vedotin in relapsed primary mediastinal large B-cell lymphoma: results from a phase 2 clinical trial 142
Growth of Chinese Italian Infants in the first 2 years of life. 141
Bendamustine efficacy in Hodgkin lymphoma patients relapsed/refractory to brentuximab vedotin. 141
Complete response of relapsed systemic and cutaneous anaplastic large cell lymphoma using brentuximab vedotin: 2 case reports. 141
Long-term efficacy and toxicity results of the FLUMIZ trial (fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in untreated follicular lymphoma). 140
Extranodal marginal zone B-cell lymphoma of the lung: experience with fludarabine and mitoxantrone-containing regimens. 139
Lenalidomide in Pretreated Mantle Cell Lymphoma Patients: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice (the Lenamant Study) 138
Efficacy of idelalisib as bridge to allogeneic stem cell transplant in relapsed follicular lymphoma: a case report 137
Management of central nervous system relapse in a young patient affected by primary mediastinal large B-cell lymphoma: A case report 137
Role of gut microbiome in the outcome of lymphoma patients treated with checkpoint inhibitors-The MicroLinf Study 136
Histological findings in patients with suspected mediastinal lymphoma relapse according to positive positron emission tomography scan during follow-up: a large retrospective analysis in 96 patients 136
A Case of Bing-Neel Syndrome Treated Successfully With Ibrutinib Monotherapy Following Intensive Chemoimmunotherapy 135
Treatment and outcomes of primary mediastinal B cell lymphoma: a three-decade monocentric experience with 151 patients 134
The Prognostic value of tumor and microenvironment markers in classifical Hodgkin lymphoma (CHL) patients. 132
The efficacy of lenalidomide combination therapy in heavily pretreated non-Hodgkin lymphoma patients: an Italian observational, multicenter, retrospective study 129
Impressive Response to Pixantrone after Allogeneic Transplant in a Multiple Relapsed Diffuse Large B-Cell Lymphoma 129
Long-term efficacy of immune checkpoint inhibitors for relapsed primary mediastinal B-cell lymphoma: a real-world study 128
Romidepsin in relapsed/refractory T-cell lymphomas: Italian experience and results of a named patient program 128
Interesting activity of pegylated liposomal doxorubicin in primary refractory and multirelapsed Hodgkin lymphoma patients: Bridge to transplant 128
Hodgkin lymphoma presenting with paraneoplastic myasthenia: a case report 128
Droplet digital polymerase chain reaction for the assessment of disease burden in hairy cell leukemia 128
The Treatment of Burkitt Lymphoma With the Berlin-Frankfurt-Münster Protocol With Rituximab and Consolidative Autologous Transplantation 127
Severe peripheral motor neuropathy in a patient with Hodgkin lymphoma treated with brentuximab vedotin. 127
Safety and Efficacy of Single-Agent Bendamustine After Failure of Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin's Lymphoma: Experience With 27 Patients. 126
Short-course R-CHOP followed by (90)Y-Ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients: 7-year long-term results 126
Efficacy and Safety of Frontline Single‐Agent Rituximab in Extranodal Marginal Zone Lymphoma 125
Single-Agent Lenalidomide Is Effective in the Treatment of a Heavily Pretreated and Refractory Angioimmunoblastic T-Cell Lymphoma Patient. 124
Prolonged disease-free survival in elderly relapsed diffuse large B-cell lymphoma patients treated with lenalidomide plus rituximab 124
Outpatient experience with biosimilar filgrastim in patients with lymphoid neoplasm: Lessons from daily clinical practice 124
Peripheral T-cell lymphomas: Focusing on novel agents in relapsed and refractory disease 123
Hairy cell leukemia: evaluation of the long-term outcome in 121 patients. 123
Primary ocular adnexal lymphomas: a retrospective study of 25 patients. 122
Multisystemic and Multiresistant Langerhans Cell Histiocytosis: A Case Treated With BRAF Inhibitor 121
Clinical Features and Treatment Outcomes of Primary Cutaneous B-cell Lymphomas: A Thirty-year Experience 120
Diagnostic accuracy of positron emission tomography/computed tomography-driven biopsy for the diagnosis of lymphoma 119
Chronic lymphocytic leukemia focus in the context of a cardiac mass in a pretreated patient: an exceptional incidental finding 119
Body image patterns, self awareness and physical growth. Preliminary notes 118
Weight status and body image perception in Italian children. 118
The prognostic value of biologic markers in classical hodgkin lymphoma (CHL) patients. 117
Long-term efficacy of the combination of lenalidomide and rituximab in elderly relapsed/refractory diffuse large B-cell lymphoma patients. 117
Potential survival benefit for patients receiving autologous hematopoietic stem cell transplantation after checkpoint inhibitors for relapsed/refractory Hodgkin lymphoma: A real-life experience 117
Successful Bridging to Allogeneic Transplantation With Valemetostat in Two Refractory/relapsed Peripheral T-cell lymphoma patients 116
Impressive continuous complete response after mogamulizumab in a heavily pretreated Sézary syndrome patient 115
Fludarabine-mitoxantrone-rituximab regimen in untreated intermediate/high-risk follicular non-Hodgkin's lymphoma: experience on 142 patients. 112
Fat Patterning in Italian and Spanish School-children 110
Lenalidomide monotherapy in heavily pretreated patients with non-Hodgkin lymphoma: an Italian observational multicenter retrospective study in daily clinical practice. 110
Primary Bone Lymphoma: Evaluation odf Chemoimmunotherapy as Front-line Treatment in 21 Patients 109
Body image and growth in Italy. 108
The treatment of hairy cell leukemia with a focus on long lasting responses to cladribine: A 30-year experience 108
Further strategies after immune checkpoint inhibitors in relapsed/refractory Hodgkin lymphoma: salvage treatments and consolidation with transplantation, experience in daily clinical practice 107
Lenalidomide Combination Therapy in Relapsed/Refractory Diffuse Large B Cell Lymphoma: The Italian Real-Life Experience 107
Early interim 18F-FDG PET in Hodgkin's lymphoma: evaluation on 304 patients. 106
Totale 16.117
Salva come PNG Salva come JPEG
Categoria #
all - tutte 60.302
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 60.302
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.252 0 0 0 0 0 61 12 74 207 73 94 731
2021/20222.408 211 81 142 249 207 114 46 189 80 178 508 403
2022/20232.856 278 417 189 380 218 214 82 226 433 94 182 143
2023/2024927 86 165 77 111 73 117 63 44 30 73 37 51
2024/20253.998 164 510 352 269 652 183 391 124 98 316 149 790
2025/20265.080 645 783 738 554 865 1.495 0 0 0 0 0 0
Totale 20.770